Nobuhiro Takagi

2.2k total citations · 1 hit paper
21 papers, 1.7k citations indexed

About

Nobuhiro Takagi is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Nobuhiro Takagi has authored 21 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Rheumatology, 6 papers in Hematology and 4 papers in Immunology. Recurrent topics in Nobuhiro Takagi's work include Rheumatoid Arthritis Research and Therapies (11 papers), Systemic Lupus Erythematosus Research (5 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Nobuhiro Takagi is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (11 papers), Systemic Lupus Erythematosus Research (5 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Nobuhiro Takagi collaborates with scholars based in Japan, United States and United Kingdom. Nobuhiro Takagi's co-authors include Norihiro Nishimoto, Kimio Terao, Toru Mima, Hideko Nakahara, Kyoko Ito, Masahiko Mihara, Tadamitsu Kishimoto, Kazuyuki Yoshizaki, Yasuhisa Takeda and Yoshiyuki Ohsugi and has published in prestigious journals such as Blood, Biochemical and Biophysical Research Communications and Annals of the Rheumatic Diseases.

In The Last Decade

Nobuhiro Takagi

21 papers receiving 1.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

2008 587 citations Norihiro Nishimoto, Kimio Terao et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nobuhiro Takagi Japan	13	744	534	449	388	259	21	1.7k
N. Miyasaka Japan	25	1.3k 1.7×	939 1.8×	406 0.9×	532 1.4×	420 1.6×	76	2.8k
Consuelo Blosch United States	8	788 1.1×	571 1.1×	485 1.1×	463 1.2×	509 2.0×	11	2.1k
Robert E. Ettlinger United States	8	778 1.0×	394 0.7×	222 0.5×	367 0.9×	238 0.9×	8	1.5k
Frances Humby United Kingdom	22	1.1k 1.5×	864 1.6×	315 0.7×	280 0.7×	354 1.4×	60	2.2k
P. P. Tak Netherlands	19	917 1.2×	760 1.4×	286 0.6×	265 0.7×	411 1.6×	38	2.0k
Janneke Tekstra Netherlands	19	683 0.9×	502 0.9×	214 0.5×	191 0.5×	162 0.6×	56	1.3k
Antonio Manzo Italy	30	1.3k 1.8×	1.2k 2.2×	599 1.3×	246 0.6×	449 1.7×	72	3.0k
Alejandro Ruı́z-Argüelles Mexico	28	393 0.5×	724 1.4×	219 0.5×	779 2.0×	352 1.4×	115	2.0k
Shoichi Ozaki Japan	31	748 1.0×	691 1.3×	217 0.5×	163 0.4×	631 2.4×	103	2.5k
Daniel Goldman United States	25	1.0k 1.4×	1.1k 2.1×	190 0.4×	139 0.4×	453 1.7×	64	2.1k

Countries citing papers authored by Nobuhiro Takagi

Since Specialization

Citations

This map shows the geographic impact of Nobuhiro Takagi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nobuhiro Takagi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nobuhiro Takagi more than expected).

Fields of papers citing papers by Nobuhiro Takagi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nobuhiro Takagi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nobuhiro Takagi. The network helps show where Nobuhiro Takagi may publish in the future.

Co-authorship network of co-authors of Nobuhiro Takagi

This figure shows the co-authorship network connecting the top 25 collaborators of Nobuhiro Takagi. A scholar is included among the top collaborators of Nobuhiro Takagi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nobuhiro Takagi. Nobuhiro Takagi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Takagi, Nobuhiro, et al.. (2019). Determination of Flufenacet and Its Metabolites in Agricultural Products by LC-MS/MS. Food Hygiene and Safety Science (Shokuhin Eiseigaku Zasshi). 60(1). 1–6. 3 indexed citations

2.

Atsumi, Tatsuya, et al.. (2017). Prodromal signs and symptoms of serious infections with tocilizumab treatment for rheumatoid arthritis: Text mining of the Japanese postmarketing adverse event-reporting database. Modern Rheumatology. 28(3). 435–443. 8 indexed citations

3.

Ishiguro, Naoki, Tatsuya Atsumi, Masayoshi Harigai, et al.. (2016). Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study. Modern Rheumatology. 27(2). 217–226. 25 indexed citations

4.

Yamamoto, Kazuhiko, Hajime Goto, Ayako Nakajima, et al.. (2015). SAT0194 Long Term Safety for Tocilizumab in Real-World Setting; 3 Year Follow-Up Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan. Annals of the Rheumatic Diseases. 74. 725–726. 1 indexed citations

5.

Nishimoto, Norihiro, Kyoko Ito, & Nobuhiro Takagi. (2010). Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Modern Rheumatology. 20(3). 222–232. 127 indexed citations

6.

Nishimoto, Norihiro & Nobuhiro Takagi. (2010). Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study. Modern Rheumatology. 20(6). 539–547. 16 indexed citations

7.

Nishimoto, Norihiro & Nobuhiro Takagi. (2010). Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study. Modern Rheumatology. 20(6). 539–547. 29 indexed citations

8.

Nishimoto, Norihiro, Kyoko Ito, & Nobuhiro Takagi. (2010). Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Modern Rheumatology. 20(3). 222–232. 100 indexed citations

9.

Nishimoto, Norihiro, et al.. (2008). Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 112(10). 3959–3964. 587 indexed citations breakdown →

10.

Nishimoto, Norihiro, Kazuyuki Yoshizaki, Keiji Maeda, et al.. (2003). Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study.. PubMed. 30(7). 1426–35. 161 indexed citations

11.

Mihara, Masahiko, et al.. (2002). Polyglutamation of a novel antifolate, MX-68, is not necessary for its anti-arthritic effect. European Journal of Pharmacology. 435(2-3). 237–244. 4 indexed citations

12.

Mihara, Masahiko, Norihiro Nishimoto, Yasuhiro Oda, et al.. (2001). Humanized Antibody to Human Interleukin-6 Receptor Inhibits the Development of Collagen Arthritis in Cynomolgus Monkeys. Clinical Immunology. 98(3). 319–326. 79 indexed citations

13.

Aoki, Akiko, Eri Hagiwara, Akihiro Ueda, et al.. (2001). [Case report of systemic lupus erythematosus patient with hemophagocytic syndrome, treated with plasma exchange, with specific reference to clinical profile and serum cytokine levels].. PubMed. 41(6). 945–50. 7 indexed citations

14.

Takagi, Nobuhiro, Masahiko Mihara, Yoichiro Moriya, et al.. (1998). Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis & Rheumatism. 41(12). 2117–2121. 11 indexed citations

15.

Takagi, Nobuhiro, Masahiko Mihara, Yoichiro Moriya, et al.. (1998). Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis & Rheumatism. 41(12). 2117–2121. 243 indexed citations

16.

Mihara, Masahiko, Nobuhiro Takagi, Yasuaki Takeda, & Y Ohsugi. (1998). IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clinical & Experimental Immunology. 112(3). 397–402. 127 indexed citations

17.

Mihara, Masahiko, et al.. (1997). Preventive effect of a novel antifolate, MX-68, in murine systemic lupus erythematosus (SLE). International Journal of Immunopharmacology. 19(2). 67–74. 3 indexed citations

18.

Yabana, Machiko, et al.. (1997). [A case of nephrotic syndrome after bone marrow transplantation].. PubMed. 39(4). 414–20. 12 indexed citations

19.

Mihara, Masahiko, et al.. (1996). In vitro and in vivo biological activities of a novel nonpolyglutamable anti-folate, MX-68. Immunopharmacology. 35(1). 41–46. 17 indexed citations

20.

Iwamoto, Tamio, et al.. (1994). Identification of Adenosine A2 Receptor-cAMP System in Human Aortic Endothelial Cells. Biochemical and Biophysical Research Communications. 199(2). 905–910. 87 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact